WAT

Waters Corporation
NYSEHEALTHCAREDIAGNOSTICS & RESEARCH

Key Statistics

Market Cap
$40.20B
P/E Ratio
104.17
EPS
$3.93
Beta
1.19
52W High
$426.22
52W Low
$282.77
50-Day MA
$391.71
200-Day MA
$360.77
Dividend Yield
Profit Margin
3.59%
Forward P/E
24.33
PEG Ratio
1.54

About Waters Corporation

Waters Corporation is a publicly traded Analytical Laboratory instrument and software company headquartered in Milford, Massachusetts.

Official WebsiteUSAFY End: December

Fundamentals

Revenue (TTM)$4.64B
Gross Profit (TTM)$2.62B
EBITDA$1.45B
Operating Margin9.42%
Return on Equity1.92%
Return on Assets3.56%
Revenue/Share (TTM)$62.10
Book Value$154.70
Price-to-Book2.67
Price-to-Sales (TTM)8.65
EV/Revenue9.8
EV/EBITDA47.04
Quarterly Earnings Growth (YoY)-3.10%
Quarterly Revenue Growth (YoY)113.40%
Shares Outstanding$98.19M
Float$98.06M
% Insiders0.10%
% Institutions102.38%

Historical Volatility

HV 10-Day
20.01%
HV 20-Day
23.88%
HV 30-Day
27.94%
HV 60-Day
26.73%
HV Rank
22.6%

Volatility is currently contracting

Analyst Ratings

Consensus ($440.65 target)
3
Strong Buy
14
Buy
7
Hold

Latest News

Invesco Discovery Mid Cap Growth Fund Q2 2026 Portfolio Performance

Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.

Seeking Alpha8/23/2026Positive
Waters (WAT) Q2 Earnings and Revenues Beat Estimates

Waters (WAT) came out with quarterly earnings of $3.05 per share, beating the Zacks Consensus Estimate of $3.01 per share. This compares to earnings of $2.95 per share a year ago.

Zacks Investment Research8/4/2026Positive
Waters Corporation (NYSE: WAT) Reports Second Quarter 2026 Financial Results

Second Quarter 2026 Highlights Total reported revenue of $1.645 billion surpassed the high end of the guidance range, driven by broad-based outperformance across both organic revenue and the acquired businesses. Organic revenue of $828 million grew 7% as reported and 9% in constant currency; the Analytical Sciences Division (ASD) delivered 8% instrument growth and double-digit chemistry consumables growth, led by low-double-digit growth in both Pharma and A&G end markets, in constant currency, as the market recovery has entered a broader phase, expanding across additional customer segments.

PRNewsWire8/4/2026Neutral
Madison Mid Cap Fund Q2 2026 Portfolio Activity

The top five contributors for the quarter were MKS, Amphenol, Arista Networks, Bio-Techne, and Waters. The bottom five detractors for the quarter were Ross Stores, Arch Capital, Copart, Gartner, and Brown & Brown. We purchased shares in Verisk Analytics, the dominant provider of data and analytics to property and casualty insurers in the U.S.

Seeking Alpha7/31/2026Neutral

Turn research into an automated options-selling system

Tiblio connects your broker and runs your put-and-call-writing strategy for you — on WAT and any ticker you trade — then tracks every position and per-strategy win rate.

See how it works

More HEALTHCARE Stocks

Data last updated: 9/7/2026